LanZhou Foci Pharmaceutical Co.,Ltd.

SZSE:002644 Stock Report

Market Cap: CN¥4.5b

LanZhou Foci PharmaceuticalLtd Valuation

Is 002644 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002644 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002644 (CN¥8.75) is trading above our estimate of fair value (CN¥8.13)

Significantly Below Fair Value: 002644 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002644?

Key metric: As 002644 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 002644. This is calculated by dividing 002644's market cap by their current earnings.
What is 002644's PE Ratio?
PE Ratio96.8x
EarningsCN¥46.18m
Market CapCN¥4.47b

Price to Earnings Ratio vs Peers

How does 002644's PE Ratio compare to its peers?

The above table shows the PE ratio for 002644 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.8x
301277 Newland Pharmaceutical
24.4xn/aCN¥4.0b
002728 Teyi Pharmaceutical GroupLtd
61.5x47.2%CN¥4.3b
603676 Tibet Weixinkang Medicine
16.7xn/aCN¥4.1b
603207 Shanghai Xiao Fang PharmaceuticalLtd
20.6xn/aCN¥4.0b
002644 LanZhou Foci PharmaceuticalLtd
96.8xn/aCN¥4.5b

Price-To-Earnings vs Peers: 002644 is expensive based on its Price-To-Earnings Ratio (96.8x) compared to the peer average (30.8x).

Price to Earnings Ratio vs Industry

How does 002644's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
002644 96.8xIndustry Avg. 31.1xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 002644 is expensive based on its Price-To-Earnings Ratio (96.8x) compared to the CN Pharmaceuticals industry average (31.1x).

Price to Earnings Ratio vs Fair Ratio

What is 002644's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002644 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio96.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 002644's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

7D

-4.2%

1Y

-23.6%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

7D

-3.0%

1Y

13.2%